Reactivation of Estrogen Receptor α by Vorinostat Sensitizes Mesenchymal-Like Triple-Negative Breast Cancer to Aminoflavone, a Ligand of the Aryl Hydrocarbon Receptor

PLoS ONE

Volumn 8, Issue 9, 2013, Pages

  Stark, Karri ^a   Burger, Angelika ^a   Wu, Jianmei ^a   Shelton, Phillip ^b   Polin, Lisa ^a   Li, Jing ^a  

^a WAYNE STATE UNIVERSITY   (United States)

^b UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AFP 464; ANTINEOPLASTIC AGENT; ESTROGEN RECEPTOR ALPHA; SMALL INTERFERING RNA; UNCLASSIFIED DRUG; VORINOSTAT;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CELL PROLIFERATION; CONTROLLED STUDY; CYP1A1 GENE; DRUG ANTAGONISM; DRUG CYTOTOXICITY; DRUG MECHANISM; DRUG POTENCY; DRUG SENSITIVITY; DRUG TOLERABILITY; FEMALE; GENE; GENE EXPRESSION PROFILING; GENE INDUCTION; GENE SILENCING; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOFLUORESCENCE; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; MOUSE; MULTIPLE CYCLE TREATMENT; NONHUMAN; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TRIPLE NEGATIVE BREAST CANCER; TUMOR XENOGRAFT; WESTERN BLOTTING;

ANIMALS; CELL LINE, TUMOR; CELL PROLIFERATION; CYTOPLASM; DRUG SYNERGISM; ESTROGEN RECEPTOR ALPHA; FEMALE; FLAVONOIDS; FLUORESCENT ANTIBODY TECHNIQUE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; HYDROXAMIC ACIDS; LIGANDS; MESODERM; MICE; MICE, INBRED BALB C; RECEPTORS, ARYL HYDROCARBON; TRANSCRIPTION, GENETIC; TRIPLE NEGATIVE BREAST NEOPLASMS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84884125735     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0074525     Document Type: Article

References (58)

1. Meng LH, Kohn KW, Pommier Y, (2007) Dose-response transition from cell cycle arrest to apoptosis with selective degradation of Mdm2 and p21WAF1/CIP1 in response to the novel anticancer agent, aminoflavone (NSC 686,288). Oncogene 26: 4806-4816.
2. Meng LH, Kohlhagen G, Liao ZY, Antony S, Sausville E, et al. (2005) DNA-protein cross-links and replication-dependent histone H2AX phosphorylation induced by aminoflavone (NSC 686288), a novel anticancer agent active against human breast cancer cells. Cancer Res 65: 5337-5343.
3. Kuffel MJ, Schroeder JC, Pobst LJ, Naylor S, Reid JM, et al. (2002) Activation of the antitumor agent aminoflavone (NSC 686288) is mediated by induction of tumor cell cytochrome P450 1A1/1A2. Mol Pharmacol 62: 143-153.
4. Loaiza-Perez AI, Kenney S, Boswell J, Hollingshead M, Alley MC, et al. (2004) Aryl hydrocarbon receptor activation of an antitumor aminoflavone: basis of selective toxicity for MCF-7 breast tumor cells. Mol Cancer Ther 3: 715-725.
5. Loaiza-Perez AI, Kenney S, Boswell J, Hollingshead M, Hose C, et al. (2004) Sensitivity of renal cell carcinoma to aminoflavone: role of CYP1A1. J Urol 171: 1688-1697.
6. Meng LH, Shankavaram U, Chen C, Agama K, Fu HQ, et al. (2006) Activation of aminoflavone (NSC 686288) by a sulfotransferase is required for the antiproliferative effect of the drug and for induction of histone gamma-H2AX. Cancer Res 66: 9656-9664.
7. Denison MS, Nagy SR, (2003) Activation of the aryl hydrocarbon receptor by structurally diverse exogenous and endogenous chemicals. Annu Rev Pharmacol Toxicol 43: 309-334.
8. Petrulis JR, Perdew GH, (2002) The role of chaperone proteins in the aryl hydrocarbon receptor core complex. Chem Biol Interact 141: 25-40.
9. Hankinson O, (2005) Role of coactivators in transcriptional activation by the aryl hydrocarbon receptor. Arch Biochem Biophys 433: 379-386.
10. Beischlag TV, Luis Morales J, Hollingshead BD, Perdew GH, (2008) The aryl hydrocarbon receptor complex and the control of gene expression. Crit Rev Eukaryot Gene Expr 18: 207-250.
11. Stark K, Nguyen B, Shelton P, Polin L, LoRusso P,et al. Cytoplasmic expression of the aryl hydrocarbon receptor elicits sensitivity and nuclear expression resistance to aminoflavone prodrug 2010 April 17-21, 2010; Washington DC, USA.
12. Lehmann BD, Bauer JA, Chen X, Sanders ME, Chakravarthy AB, et al. (2011) Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. J Clin Invest 121: 2750-2767.
13. Neve RM, Chin K, Fridlyand J, Yeh J, Baehner FL, et al. (2006) A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes. Cancer Cell 10: 515-527.
14. Shelton PM, Nguyen B, Chen A, Burger AM, (2009) Transcriptional gene expression profiles indicate response of breast Cancer cell lines to aminoflavone prodrug. Cancer Research 69: 2153.
15. Wilson MK, Stone E, Vitolo M (2006) Response of breast cancer cell lines to aminoflavone (NSC 686288) is associated with histone H2AX phosphorylation and estrogen receptor expression; April 2006; Washington DC, USA. pp. abstrat 555.
16. Jang ER, Lim SJ, Lee ES, Jeong G, Kim TY, et al. (2004) The histone deacetylase inhibitor trichostatin A sensitizes estrogen receptor alpha-negative breast cancer cells to tamoxifen. Oncogene 23: 1724-1736.
17. Sharma D, Saxena NK, Davidson NE, Vertino PM, (2006) Restoration of tamoxifen sensitivity in estrogen receptor-negative breast cancer cells: tamoxifen-bound reactivated ER recruits distinctive corepressor complexes. Cancer Res 66: 6370-6378.
18. Willmarth NE, Ethier SP, (2006) Autocrine and juxtacrine effects of amphiregulin on the proliferative, invasive, and migratory properties of normal and neoplastic human mammary epithelial cells. J Biol Chem 281: 37728-37737.
19. Forozan F, Veldman R, Ammerman CA, Parsa NZ, Kallioniemi A, et al. (1999) Molecular cytogenetic analysis of 11 new breast cancer cell lines. Br J Cancer 81: 1328-1334.
20. Miller FR, Soule HD, Tait L, Pauley RJ, Wolman SR, et al. (1993) Xenograft model of progressive human proliferative breast disease. J Natl Cancer Inst 85: 1725-1732.
21. Mosmann T, (1983) Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods 65: 55-63.
22. Chou TC, (2006) Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies. Pharmacol Rev 58: 621-681.
23. Vassal G, Merlin JL, Terrier-Lacombe MJ, Grill J, Parker F, et al. (2003) In vivo antitumor activity of S16020, a topoisomerase II inhibitor, and doxorubicin against human brain tumor xenografts. Cancer Chemother Pharmacol 51: 385-394.
24. Wu X, Hawse JR, Subramaniam M, Goetz MP, Ingle JN, et al. (2009) The tamoxifen metabolite, endoxifen, is a potent antiestrogen that targets estrogen receptor alpha for degradation in breast cancer cells. Cancer Res 69: 1722-1727.
25. Yang X, Phillips DL, Ferguson AT, Nelson WG, Herman JG, et al. (2001) Synergistic activation of functional estrogen receptor (ER)-alpha by DNA methyltransferase and histone deacetylase inhibition in human ER-alpha-negative breast cancer cells. Cancer Res 61: 7025-7029.
26. Marks PA, (2007) Discovery and development of SAHA as an anticancer agent. Oncogene 26: 1351-1356.
27. Richon VM, Emiliani S, Verdin E, Webb Y, Breslow R, et al. (1998) A class of hybrid polar inducers of transformed cell differentiation inhibits histone deacetylases. Proc Natl Acad Sci U S A 95: 3003-3007.
28. Bolden JE, Peart MJ, Johnstone RW, (2006) Anticancer activities of histone deacetylase inhibitors. Nat Rev Drug Discov 5: 769-784.
29. Yang X, Ferguson AT, Nass SJ, Phillips DL, Butash KA, et al. (2000) Transcriptional activation of estrogen receptor alpha in human breast cancer cells by histone deacetylase inhibition. Cancer Res 60: 6890-6894.
30. Zhou Q, Atadja P, Davidson NE, (2007) Histone deacetylase inhibitor LBH589 reactivates silenced estrogen receptor alpha (ER) gene expression without loss of DNA hypermethylation. Cancer Biol Ther 6: 64-69.
31. Sharma D, Blum J, Yang X, Beaulieu N, Macleod AR, et al. (2005) Release of methyl CpG binding proteins and histone deacetylase 1 from the Estrogen receptor alpha (ER) promoter upon reactivation in ER-negative human breast cancer cells. Mol Endocrinol 19: 1740-1751.
32. Rountree MR, Bachman KE, Baylin SB, (2000) DNMT1 binds HDAC2 and a new co-repressor, DMAP1, to form a complex at replication foci. Nat Genet 25: 269-277.
33. Robertson KD, Ait-Si-Ali S, Yokochi T, Wade PA, Jones PL, et al. (2000) DNMT1 forms a complex with Rb, E2F1 and HDAC1 and represses transcription from E2F-responsive promoters. Nat Genet 25: 338-342.
34. Shang Y, Hu X, DiRenzo J, Lazar MA, Brown M, (2000) Cofactor dynamics and sufficiency in estrogen receptor-regulated transcription. Cell 103: 843-852.
35. Brunnberg S, Pettersson K, Rydin E, Matthews J, Hanberg A, et al. (2003) The basic helix-loop-helix-PAS protein ARNT functions as a potent coactivator of estrogen receptor-dependent transcription. Proc Natl Acad Sci U S A 100: 6517-6522.
36. Ohtake F, Takeyama K, Matsumoto T, Kitagawa H, Yamamoto Y, et al. (2003) Modulation of oestrogen receptor signalling by association with the activated dioxin receptor. Nature 423: 545-550.
37. Paech K, Webb P, Kuiper GG, Nilsson S, Gustafsson J, et al. (1997) Differential ligand activation of estrogen receptors ERalpha and ERbeta at AP1 sites. Science 277: 1508-1510.
38. Saville B, Wormke M, Wang F, Nguyen T, Enmark E, et al. (2000) Ligand-, cell-, and estrogen receptor subtype (alpha/beta)-dependent activation at GC-rich (Sp1) promoter elements. J Biol Chem 275: 5379-5387.
39. Wihlen B, Ahmed S, Inzunza J, Matthews J, (2009) Estrogen receptor subtype- and promoter-specific modulation of aryl hydrocarbon receptor-dependent transcription. Mol Cancer Res 7: 977-986.
40. Matthews J, Wihlen B, Thomsen J, Gustafsson JA, (2005) Aryl hydrocarbon receptor-mediated transcription: ligand-dependent recruitment of estrogen receptor alpha to 2,3,7,8-tetrachlorodibenzo-p-dioxin-responsive promoters. Mol Cell Biol 25: 5317-5328.
41. Beischlag TV, Perdew GH, (2005) ER alpha-AHR-ARNT protein-protein interactions mediate estradiol-dependent transrepression of dioxin-inducible gene transcription. J Biol Chem 280: 21607-21611.
42. Safe S, Wormke M, (2003) Inhibitory aryl hydrocarbon receptor-estrogen receptor alpha cross-talk and mechanisms of action. Chem Res Toxicol 16: 807-816.
43. Matthews J, Gustafsson JA, (2006) Estrogen receptor and aryl hydrocarbon receptor signaling pathways. Nucl Recept Signal 4: e016.
44. Vickers PJ, Dufresne MJ, Cowan KH, (1989) Relation between cytochrome P450IA1 expression and estrogen receptor content of human breast cancer cells. Mol Endocrinol 3: 157-164.
45. Thomsen JS, Nissen L, Stacey SN, Hines RN, Autrup H, (1991) Differences in 2,3,7,8-tetrachlorodibenzo-p-dioxin-inducible CYP1A1 expression in human breast carcinoma cell lines involve altered trans-acting factors. Eur J Biochem 197: 577-582.
46. Spink DC, Katz BH, Hussain MM, Pentecost BT, Cao Z, et al. (2003) Estrogen regulates Ah responsiveness in MCF-7 breast cancer cells. Carcinogenesis 24: 1941-1950.
47. Thomsen JS, Wang X, Hines RN, Safe S, (1994) Restoration of aryl hydrocarbon (Ah) responsiveness in MDA-MB-231 human breast cancer cells by transient expression of the estrogen receptor. Carcinogenesis 15: 933-937.
48. Wang WL, Thomsen JS, Porter W, Moore M, Safe S, (1996) Effect of transient expression of the oestrogen receptor on constitutive and inducible CYP1A1 in Hs578T human breast cancer cells. Br J Cancer 73: 316-322.
49. Gui CY, Ngo L, Xu WS, Richon VM, Marks PA, (2004) Histone deacetylase (HDAC) inhibitor activation of p21WAF1 involves changes in promoter-associated proteins, including HDAC1. Proc Natl Acad Sci U S A 101: 1241-1246.
50. Xu WS, Parmigiani RB, Marks PA, (2007) Histone deacetylase inhibitors: molecular mechanisms of action. Oncogene 26: 5541-5552.
51. Chambers AE, Banerjee S, Chaplin T, Dunne J, Debernardi S, et al. (2003) Histone acetylation-mediated regulation of genes in leukaemic cells. Eur J Cancer 39: 1165-1175.
52. Glaser KB, Staver MJ, Waring JF, Stender J, Ulrich RG, et al. (2003) Gene expression profiling of multiple histone deacetylase (HDAC) inhibitors: defining a common gene set produced by HDAC inhibition in T24 and MDA carcinoma cell lines. Mol Cancer Ther 2: 151-163.
53. Mitsiades CS, Mitsiades NS, McMullan CJ, Poulaki V, Shringarpure R, et al. (2004) Transcriptional signature of histone deacetylase inhibition in multiple myeloma: biological and clinical implications. Proc Natl Acad Sci U S A 101: 540-545.
54. Peart MJ, Smyth GK, van Laar RK, Bowtell DD, Richon VM, et al. (2005) Identification and functional significance of genes regulated by structurally different histone deacetylase inhibitors. Proc Natl Acad Sci U S A 102: 3697-3702.
55. Sasakawa Y, Naoe Y, Sogo N, Inoue T, Sasakawa T, et al. (2005) Marker genes to predict sensitivity to FK228, a histone deacetylase inhibitor. Biochem Pharmacol 69: 603-616.
56. Tate CR, Rhodes LV, Segar HC, Driver JL, Pounder FN, et al. (2012) Targeting triple-negative breast cancer cells with the histone deacetylase inhibitor panobinostat. Breast Cancer Res 14: R79.
57. Bauer JA, Chakravarthy AB, Rosenbluth JM, Mi D, Seeley EH, et al. (2010) Identification of markers of taxane sensitivity using proteomic and genomic analyses of breast tumors from patients receiving neoadjuvant paclitaxel and radiation. Clin Cancer Res 16: 681-690.
58. Juul N, Szallasi Z, Eklund AC, Li Q, Burrell RA, et al. (2010) Assessment of an RNA interference screen-derived mitotic and ceramide pathway metagene as a predictor of response to neoadjuvant paclitaxel for primary triple-negative breast cancer: a retrospective analysis of five clinical trials. Lancet Oncol 11: 358-365.